Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633134 | 0.81 | TOP2A (0.42) | TOP2AALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL5632025 | 0.80 | PPARD (0.50) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL5632759 | 0.80 | PPARA (0.52) | ELANE | |
| SCHEMBL5633651 | 0.78 | LMNA (0.38) | ALDH1A1KDM4EGAASMN1; SMN2HTT | |
| SCHEMBL5633706 | 0.76 | POLQ (0.48) | LMNA | |
| SCHEMBL4806424 | 0.76 | CYP2D6 (0.50) | ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5702322 | 0.75 | HDAC3 (0.41) | ALDH1A1KDM4EGAAMAPK8ELANE | |
| SCHEMBL5632004 | 0.74 | HCAR3 (0.43) | MEN1KMT2AMAPTSMN1; SMN2HTT | |
| SCHEMBL14422810 | 0.73 | PPARD (0.41) | TOP2AALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL5677763 | 0.72 | KCNH2 (0.44) | ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208026-A1 | N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders | KALYPSYS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208026-A1 | N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders | KALYPSYS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208026-A1 | N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders | KALYPSYS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2004092130-A2 | N-CONTAINING HETEROAROMATIC COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208026-A1 | N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders | PPARG, PPARA, PPARD | TOP2A 2061/4885ALDH1A1 877/4885MEN1 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.